NKGen Biotech, Inc. (NASDAQ:NKGNW) Sees Significant Decrease in Short Interest

NKGen Biotech, Inc. (NASDAQ:NKGNW) was the target of a significant decrease in short interest in the month of December. As of December 15th, there was short interest totalling 1,700 shares, a decrease of 89.7% from the November 30th total of 16,500 shares. Based on an average daily trading volume, of 12,800 shares, the short-interest ratio is presently 0.1 days.

NKGen Biotech Stock Performance

Shares of NASDAQ NKGNW traded up $0.00 during midday trading on Thursday, reaching $0.08. 68,020 shares of the company were exchanged, compared to its average volume of 18,079. NKGen Biotech has a 1 year low of $0.02 and a 1 year high of $0.29. The stock has a fifty day simple moving average of $0.05 and a 200 day simple moving average of $0.07.

NKGen Biotech Company Profile

NKGen Biotech, Inc operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials.